EE05328B1 - Meetod amorfse atorvastatiini valmistamiseks - Google Patents

Meetod amorfse atorvastatiini valmistamiseks

Info

Publication number
EE05328B1
EE05328B1 EEP200200293A EEP200200293A EE05328B1 EE 05328 B1 EE05328 B1 EE 05328B1 EE P200200293 A EEP200200293 A EE P200200293A EE P200200293 A EEP200200293 A EE P200200293A EE 05328 B1 EE05328 B1 EE 05328B1
Authority
EE
Estonia
Prior art keywords
atorvastatin
solvent
preparation
type
amorphous form
Prior art date
Application number
EEP200200293A
Other languages
English (en)
Estonian (et)
Inventor
Pflaum Zlatko
Original Assignee
Lek Pharmaceutical And Chemical Company, D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company, D.D. filed Critical Lek Pharmaceutical And Chemical Company, D.D.
Publication of EE200200293A publication Critical patent/EE200200293A/xx
Publication of EE05328B1 publication Critical patent/EE05328B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200200293A 1999-12-10 2000-12-05 Meetod amorfse atorvastatiini valmistamiseks EE05328B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9900271A SI20425A (sl) 1999-12-10 1999-12-10 Priprava amorfnega atorvastatina
PCT/IB2000/001797 WO2001042209A1 (en) 1999-12-10 2000-12-05 Process for the preparation of amorphous atorvastatin

Publications (2)

Publication Number Publication Date
EE200200293A EE200200293A (et) 2003-06-16
EE05328B1 true EE05328B1 (et) 2010-08-16

Family

ID=20432564

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200293A EE05328B1 (et) 1999-12-10 2000-12-05 Meetod amorfse atorvastatiini valmistamiseks

Country Status (22)

Country Link
US (2) US6613916B2 (cs)
EP (1) EP1237864B1 (cs)
JP (1) JP5087193B2 (cs)
KR (1) KR100729689B1 (cs)
AT (1) ATE270661T1 (cs)
AU (1) AU776854B2 (cs)
BG (1) BG65719B1 (cs)
CA (1) CA2392025C (cs)
CZ (1) CZ301627B6 (cs)
DE (1) DE60012045T2 (cs)
EE (1) EE05328B1 (cs)
ES (1) ES2223615T3 (cs)
HR (1) HRP20020482B1 (cs)
PL (1) PL208226B1 (cs)
PT (1) PT1237864E (cs)
RS (1) RS50307B (cs)
RU (1) RU2247113C2 (cs)
SI (1) SI20425A (cs)
SK (1) SK287032B6 (cs)
TR (1) TR200402543T4 (cs)
UA (1) UA71041C2 (cs)
WO (1) WO2001042209A1 (cs)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191236B (cs) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (cs) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
GEP20053546B (en) 2001-06-29 2005-06-10 Warner Lambert Co Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin)
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
AU2002247944B2 (en) * 2002-03-18 2009-05-21 Biocon Limited Amorphous Hmg-CoA reductase inhibitors of desired particle size
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
AU2004228607B2 (en) * 2003-04-11 2011-01-27 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
AU2005223491A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
US7994343B2 (en) * 2004-03-17 2011-08-09 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
US20070225353A1 (en) * 2004-04-16 2007-09-27 Pfizer, Inc. Process for Forming Amorphous Atorvastatin
EP1745020A2 (en) 2004-05-05 2007-01-24 Pfizer Products Incorporated Salt forms of atorvastatin
HUE029911T2 (en) * 2004-07-16 2017-04-28 Lek Pharmaceuticals Products of atorvastatin calcium oxidative degradation
CA2754932C (en) * 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
TW200630335A (en) * 2004-10-18 2006-09-01 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
NZ554541A (en) * 2004-10-28 2011-01-28 Warner Lambert Co Process for forming amorphous atorvastatin
WO2006048888A1 (en) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Novel process for the preparation of amorphous atorvastatin calcium salt
WO2006048893A2 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited A process for synthesis of large particle size statin compounds
ES2263370B1 (es) * 2005-02-16 2007-12-01 Ercros Industrial, S.A. Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
PT1957452E (pt) * 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
CN100429202C (zh) * 2006-06-30 2008-10-29 浙江新东港药业股份有限公司 一种无定形氟伐他汀钠的制备方法
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CN101657419A (zh) * 2007-03-02 2010-02-24 东亚制药株式会社 吡咯基庚酸衍生物的新晶型
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
CN102369081B (zh) * 2009-03-30 2015-09-02 伯格利-格拉维瑞斯股份有限公司 用于使用纳秒范围内脉冲的第一激光器和皮秒或飞秒范围内脉冲的第二激光器来构造具有硬质涂覆的固体表面的方法和设备
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
MX371021B (es) * 2013-08-29 2020-01-13 Cadila Healthcare Ltd Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables.
CN106432033B (zh) * 2016-10-21 2018-07-27 江苏阿尔法药业有限公司 一种无定形阿托伐他汀钙的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE123020T1 (de) * 1990-05-11 1995-06-15 American Cyanamid Co N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe.
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
PL193479B1 (pl) 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IN191236B (cs) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina

Also Published As

Publication number Publication date
SI20425A (sl) 2001-06-30
BG65719B1 (bg) 2009-08-31
ATE270661T1 (de) 2004-07-15
US20040024046A1 (en) 2004-02-05
HRP20020482A2 (en) 2004-08-31
KR20020073137A (ko) 2002-09-19
US6891047B2 (en) 2005-05-10
ES2223615T3 (es) 2005-03-01
PL356184A1 (en) 2004-06-14
CA2392025A1 (en) 2001-06-14
DE60012045D1 (de) 2004-08-12
SK287032B6 (sk) 2009-10-07
JP5087193B2 (ja) 2012-11-28
WO2001042209A1 (en) 2001-06-14
RS50307B (sr) 2009-09-08
UA71041C2 (uk) 2004-11-15
EP1237864A1 (en) 2002-09-11
CA2392025C (en) 2009-06-02
PL208226B1 (pl) 2011-04-29
US20020183527A1 (en) 2002-12-05
CZ301627B6 (cs) 2010-05-05
BG106786A (en) 2003-05-30
EP1237864B1 (en) 2004-07-07
PT1237864E (pt) 2004-11-30
EE200200293A (et) 2003-06-16
YU36802A (sh) 2005-09-19
TR200402543T4 (tr) 2004-12-21
US6613916B2 (en) 2003-09-02
HRP20020482B1 (en) 2007-05-31
SK7832002A3 (en) 2002-11-06
AU1543801A (en) 2001-06-18
AU776854B2 (en) 2004-09-23
DE60012045T2 (de) 2005-07-07
RU2247113C2 (ru) 2005-02-27
KR100729689B1 (ko) 2007-06-18
JP2003516388A (ja) 2003-05-13

Similar Documents

Publication Publication Date Title
EE05328B1 (et) Meetod amorfse atorvastatiini valmistamiseks
DK0839132T5 (da) Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1)
MA27044A1 (fr) FORMES CRISTALLINES DE SEL DE CALCIUM(2 :1) D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO) CARBONYL]-1H-PYRROLE-1-HEPTANOiQUE (ATORVASTATINE)
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
DK1148049T3 (da) Krystallinsk [R-(R*,R*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre-hemicalciumsalt (ATORVASTATIN)
IL155890A0 (en) HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
BG108518A (en) Crystalline forms vi and vii of atorvastatin calcium
NZ533935A (en) Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1)
IL173651A0 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CA2522899A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
TH76289A (th) กระบวนการผลิตอะทอร์วาสเตตินแคลเซียมในรูปแบบอสัณฐาน

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20121205